Celyad OncologyCLYYF 28 Days Payable is 0.00 as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 28/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 707 Biotechnology companies, Celyad Oncology ranks better than 97.45% on this metric.
The historical rank and industry rank for Celyad Oncology's Days Payable or its related term are showing as below:
CLYYF'
s Days Payable Range Over the Past 10 Years
Min: 1974.7 Med: 15856.34 Max: 40530.21
Current: 40530.21
During the past 13 years, Celyad Oncology's highest Days Payable was 40530.21. The lowest was 1974.70. And the median was 15856.34.
CLYYF's Days Payable is ranked better than 97.45% of 707
companies
in the Biotechnology industry
Industry Median: 113.76
vs CLYYF: 40530.21
Celyad Oncology's Days Payable
declined
from Dec. 2024 (55,480.00) to Dec. 2025 (0.00).
It may suggest that Celyad Oncologyaccelerated paying its suppliers.
Celyad Oncology Days Payable Related Terms
Celyad Oncology Days Payable Historical Data
* Premium members only.
The historical data trend for Celyad Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLYYF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Celyad Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celyad Oncology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celyad Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where Celyad Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Celyad Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celyad Oncology (CLYYF) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celyad Oncology and its competitors. Over the past decade, Celyad Oncology's Days Payable has ranged from 1,974.70 to 40,530.21. According to the industry distribution chart, Celyad Oncology ranks #18 out of 707 companies in the Biotechnology industry, placing it in the top 2.5%.
Is Celyad Oncology's Days Payable too high?
Celyad Oncology's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 1,974.70 to a high of 40,530.21. Based on the distribution chart, Celyad Oncology ranks #18 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celyad Oncology has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Celyad Oncology ranks #18 out of 707 companies for Days Payable. This places Celyad Oncology in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.76. Historically, Celyad Oncology's own Days Payable has ranged from 1,974.70 to 40,530.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Celyad Oncology and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celyad Oncology's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Based on GuruFocus' analysis, Celyad Oncology (CLYYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $0.25 — trading 66.7% above its estimated fair value. The current Days Payable is 0.00. Celyad Oncology's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celyad Oncology (CLYYF) Overvalued in 2026?
Based on GuruFocus' analysis, Celyad Oncology stock appears to be overvalued.
The current stock price of $0.25 is trading 66.7% above its estimated GF Value™ of $0.15.
GuruFocus considers Celyad Oncology to be Significantly Overvalued.
Key valuation signals for CLYYF:
Days Payable: 0.00
GF Value™: $0.15 vs. price of $0.25 (66.7% above fair value)
No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
28GF Score
Get the complete analysis for CLYYF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLYYF has been successfully added to your 
